Centiva Capital, LP Regeneron Pharmaceuticals, Inc. Call Options Transaction History

Centiva Capital, LP

13 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1024.09 - $1201.76 $614,454 - $721,056	600 New	600 $630,000
Q1 2024 May 15, 2024	BUY	$902.69 - $993.35 $992,959 - $1.09 Million	1,100 Added 44.0%	3,600 $3.46 Million
Q4 2023 Feb 14, 2024	SELL	$775.18 - $881.7 $2.09 Million - $2.38 Million	-2,700 Reduced 51.92%	2,500 $2.2 Million
Q3 2023 Nov 14, 2023	SELL	$692.45 - $844.37 $1.11 Million - $1.35 Million	-1,600 Reduced 23.53%	5,200 $4.28 Million
Q2 2023 Aug 14, 2023	SELL	$700.03 - $830.35 $700,030 - $830,350	-1,000 Reduced 12.82%	6,800 $4.89 Million
Q1 2023 May 15, 2023	BUY	$680.49 - $826.97 $2.25 Million - $2.73 Million	3,300 Added 73.33%	7,800 $6.41 Million
Q4 2022 Feb 14, 2023	SELL	$705.89 - $766.39 $3.53 Million - $3.83 Million	-5,000 Reduced 52.63%	4,500 $3.25 Million
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $1.43 Million - $1.81 Million	2,500 Added 35.71%	9,500 $6.54 Million
Q2 2022 Aug 17, 2022	SELL	$548.35 - $738.84 $548,350 - $738,840	-1,000 Reduced 12.5%	7,000 $4.14 Million
Q1 2022 May 16, 2022	BUY	$595.12 - $698.43 $4.11 Million - $4.82 Million	6,900 Added 627.27%	8,000 $5.59 Million
Q4 2021 Feb 14, 2022	SELL	$543.48 - $670.97 $2.88 Million - $3.56 Million	-5,300 Reduced 82.81%	1,100 $695,000
Q1 2019 May 14, 2019	BUY	$372.08 - $439.57 $1.41 Million - $1.67 Million	3,800 Added 146.15%	6,400 $2.63 Million
Q4 2018 Feb 13, 2019	BUY	$335.82 - $403.04 $873,132 - $1.05 Million	2,600 New	2,600 $971,000

1,524

84M

1.14M

1.48M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $83.9B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.